Key statistics dashboard for Centessa Pharmaceuticals plc (CNTA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease.
Stock Data
| Price | $40.50 |
| Market Cap | $6.3B |
| Enterprise Value | $6.21B |
| Beta | 1.26 |
| Exchange | NASDAQ |
| Country | GB |
Valuation Multiples
| P/E Ratio | -22.75 |
| Price / Book | 12.76 |
| P/S | 0.00 |
| EV/EBITDA | -23.84 |
| EV/Sales | 0.00 |
| EV/FCF | -29.70 |
| P/FCF | -29.96 |
| Earnings Yield | -4.03% |
| FCF Yield | -3.34% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -60.37% |
| Return on Assets | -39.05% |
| Return on Invested Capital | -42.41% |
| Return on Capital Employed | -42.41% |
Financial Health
| Current Ratio | 9.53 |
| Quick Ratio | 9.53 |
| Cash Ratio | 1.71 |
| Debt / Equity | 0.02 |
| Debt / Assets | 1.15% |
| Net Debt / EBITDA | 0.21 |
| Interest Coverage | -22.70 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 9.85 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 3.17 |
| Cash per share | 1.80 |
| FCF per share | -1.36 |
| Tangible Book Value per share | 3.17 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (1-5) | 0.57 |
Related companies: CGEM · CMPX · DSGN · EWTX · GLUE · IPSC · IVA
Explore sector: Healthcare · Biotechnology
More sections of CNTA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks